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Molecular Cytogenetic Delineation of Deletions and Translocations Involving
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Stephan Stilgenbauer, Lap-Chee Tsui, Peter Lichter, and Hartmut Do¨hner
Loss of chromosome 7 (Ï7) or deletion of its long arm (7qÏ) YACs recognizing a contiguous genomic DNA fragment of 5
are recurring chromosome abnormalities in myeloid disor- to 6 Mb in band 7q22. In the 19 cases with deletions, we
ders, especially in therapy-related myelodysplastic syn- identified two distinct commonly deleted regions: one re-
drome (t-MDS) and acute myeloid leukemia (t-AML). The gion within band 7q22 was defined by the two CML cases;
association of Ï7/7qÏwith myeloid leukemia suggests that the second region encompassed a distal part of band 7q22
these regions contain a novel tumor suppressor gene(s) and the entire band 7q31 and was defined by the MDS/AML
whose loss of function contributes to leukemic transforma- cases. The breakpoint of one of the reciprocal translocations
tion or tumor progression. Based on chromosome banding was mapped to 7q21.3, which is centromeric to both of the
analysis, two critical regions have been identified: one in commonly deleted regions. The breakpoint of the second
band 7q22 and a second in bands 7q32-q35. We analyzed translocation, which was present in unstimulated bone mar-
bone marrow and blood samples from 21 patients with my- row and phytohemagglutinin-stimulated blood of an MDS
eloid leukemia (chronic myeloid leukemia, n ! 2; de novo patient, was localized to a 400-kb genomic segment in 7q22
MDS, n ! 4; de novo AML, n ! 13; t-AML, n ! 2) that on within the deletion cluster of the MDS/AML cases. In conclu-
chromosome banding analysis exhibited deletions (n ! 19) sion, our data show marked heterogeneity of 7q22 deletion
or reciprocal translocations (n ! 2) of band 7q22 using fluo-
and translocation breakpoints in myeloid leukemias, sug-rescence in situ hybridization. As probes, we used Alu-poly-
gesting the existence of more than one pathogenetically rel-merase chain reaction products from 22 yeast artificial
evant gene.chromosome (YAC) clones that span chromosome bands
q 1997 by The American Society of Hematology.7q21.1-q32, including representative clones from a panel of
L regions contain a novel tumor suppressor gene(s) whose lossof function leads to leukemic transformation. At present,OSS OF CHROMOSOME 7 (07) or deletion of its longarm (7q0) are recurring chromosome abnormalities
in myeloid disorders. These aberrations are associated with there are scarce data on the molecular characterization of
the genomic region affected by these deletions. No tumormyelodysplastic syndrome (MDS) and acute myeloid leuke-
mia (AML), in particular with therapy-related MDS/AML suppressor gene of pathogenic significance has been identi-
fied. Kere et al10,11 studied 4 patients with myeloid disorders(t-MDS/t-AML) after therapy with alkylating agents or sec-
ondary MDS/AML after occupational exposure to chemical exhibiting partial 7q deletions. Using restriction fragment
length polymorphism (RFLP) and quantitative Southern blotmutagens.1-3 Furthermore, 07/7q0 occur in MDS and AML
that develop in patients with constitutional disorders (eg, analysis, they localized the proximal breakpoints of all 4
cases between the genes for erythropoietin (EPO) and plas-Fanconi’s anemia, Kostmann’s syndrome, neurofibromatosis
type 1, and familial monosomy 7).4 Clinically, myeloid leu- minogen activator inhibitor 1 (PLANH1).10 All deletions
were interstitial, with variability of the distal breakpoints.11kemias exhibiting 07/7q0 are associated with high suscepti-
bility to infections, poor response to chemotherapy, and short In another RFLP study of 5 patients with myeloid disorders
and 7q deletions, all 5 deletions were interstitial, with greatsurvival times.1,5
Based on chromosome banding analysis, there appear to variability of the proximal and distal breakpoints.12 However,
be two critical regions on the long arm of chromosome 7: in these studies, the resolution of the deletion map was lim-
one in band 7q22 and a second in bands 7q32-q35.3,6-9 The ited because the applied probes were scattered along a large
recurrent loss of chromosome material suggests that these genomic region.
Recently, fluorescence in situ hybridization (FISH) with
mapped cosmid and yeast artificial chromosome (YAC)
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Table 1. Designation of YAC Clones, Chromosomal Localization, Size, and DNA Markers/Genes on Each YAC Clone
Name Location Size (kb) DNA Markers
HSC7E520 7q21.1 500 CACNL2A, HGF, D7S581, D7S802, D7S849, D7S2275E
HSC7E590 7q21.1-q21.2 460 D7S166, D7S195, D7S260, D7S524, D7S644, D7S2537
HSC7E481 7q21.1-q21.3 900 PGY1, PGY3, D7S269, D7S575, D7S1642, D7S1646, D7S2621, D7S2623, D7S2624, D7S2626,
D7S2628, D7S2786, Cdy11e05
HSC7E502 7q21.1-q21.3 600 D7S183, D7S492, D7S569, D7S570, D7S577
HSC7E465 7q21.3 700 CALCR, D7S15, D7S652, D7S657, D7S2430, HSC7E1275RV
HSC7E783 7q21.3-q22.1 650 ASNS, D7S82, D7S554, HSC7E1131RV, UT901
HSC7E911 7q22 580 D7S651, NIB217, 932D8.1, E911.1
HSC7E808 7q22 470 D7S647, D7S2498, D7S2832, AFMa163ya9, E808.3, CYP3A4
HSC7E914 7q22 340 D7S647, D7S2832, AFMa163ya9, CYP3A4
HSC7E737 7q22 250 PLANHI, D7S477, UT682
HSC7E791 7q22 250 CUTL1, D7S515, D7S666, D7S740, D7S2433, D7S2536
HSC7E329 7q22 380 D7S2448, APCR.HSC7E452, APCR.HSC7E570, 942E8.18
HSC7E316 7q22 440 APCR.HSC7E452, 942E8.18
HSC7E441 7q22 480 D7S76, D7S238, D7S561, D7S658, D7S796, D7S818, D7S2504
HSC7E485 7q22 540 D7S76, D7S238, D7S561, D7S562, D7S563, D7S796, D7S818
HSC7E506 7q22 520 D7S240, D7S561, D7S562, D7S563, D7S572, D7S579, D7S584, D7S2509
HSC7E572 7q22.3-q31.1 400 D7S1493, D7S1799, D7S2494
HSC7E161 7q22.3-q31.1 450 PRKAR2B, DRA, D7S496, D7S2317, D7S2459, Bdy96E06
HSC7E132 7q22.3-q31.1 650 D7S13, D7S1763, Bdy31e11
HSC7E4 7q31.2-q31.3 600 CAPZA2, MET, D7S567, D7S568, D7S1764, D7S2460
HSC7E222 7q31.3-q32.1 580 D7S480, D7S650, D7S685, D7S2821, Cdy0rd04
HSC7E1289 7q32.1 1800 GRM8, D7S514, D7S680, D7S686, D7S1498, D7S1801, D7S1822, D7S1873, D7S1874, D7S2244
HSC7E526 7q36 560 D7S68, D7S593, D7S594
The region between YAC clones HSC7E808 to HSC7E572 represents approximately 5 to 6 Mb of DNA and this region is covered completely
by an overlapping set of YAC clones.17 HSC7E914, HSC7E737, HSC7E791, HSC7E329, HSC7E316, HSC7E441, HSC7E485, and HSC7E506 are
representative clones from this contig that were chosen to be uniformly spaced throughout the region. The genes encoding EPO and ACHE are
located between clones HSC7E911 and HSC7E808.20 To mark the end of the chromosome, we used clone HSC7E526, which begins approximately
100 kb from the end of the chromosome and extends 560 kb towards the centromere.20
(PRKAR2B, DRA), HSC7E132, HSC7E4 (CAPZA2, MET),were used, it was possible to systematically delineate the
HSC7E222, and HSC7E1289 (GRM8).14-17,19,20 Information on theextent of the deletions and to locate the breakpoints of recip-
YAC clones is available at http://www.genet.sickkids.on.ca/chro-rocal translocations on the molecular level.
mosome7/.
Human sequences from the YAC clones were generated by a
MATERIALS AND METHODS polymerase chain reaction (PCR) protocol using primers directed
against Alu-sequences.21 Amplification was performed in a 100 mLPatients
reaction mixture containing approximately 160 ng YAC-DNA, 100Bone marrow and/or blood samples from 21 adult patients with
mmol/L of the four dNTPs (Boehringer Mannheim, Mannheim, Ger-
myeloid disorders that on banding analysis exhibited deletions or
many), 10 mL PCR buffer (Boehringer Mannheim), and 2.0 mmol/translocations of chromosome band 7q22 were analyzed. The diag-
L MgCl2 (Boehringer Mannheim). Three Alu-PCR reactions werenosis were as follows: chronic-phase chronic myeloid leukemia performed using either the primers CL1, CL2, or a combination of(CML), n  2 (nos. 1 and 2); de novo MDS, n  4 (nos. 3 through both (0.5 mmol/L). The products of all three reactions were combined6); de novo AML, n  13 (nos. 7 through 19); and t-AML, n  2 for the FISH experiments. The probes were labeled by nick transla-(nos. 20 and 21). G-banding analysis was performed using standard
tion with biotin-16-dUTP or digoxigenin-11-dUTP (Boehringer
methods. Images were captured and processed in the Ikaros system
Mannheim).(MetaSystems, Altlussheim, Germany) and the karyotypes were des-
ignated according to the International System for Cytogenetic No- FISH
menclature.18
FISH was performed as described.22,23 The hybridization mixture
contained approximately 250 ng labeled YAC-DNA, 10 mg Cot-1DNA Probes DNA fraction (BRL/Life Technologies, Gaithersburg, MD), and 10
mg herring sperm DNA (Boehringer Mannheim).For the interphase and metaphase FISH experiments, we selected
the following 22 YAC clones (Table 1) that were previously mapped Interphase cytogenetic analysis was performed for deletion map-
ping. To monitor the hybridization efficiency, we cohybridized withto chromosome bands 7q21.1 to 7q32 (genes that are present on
each YAC are given in parentheses): HSC7E520 (CACNL2A; HGF), a YAC clone from 7q that mapped outside the region of interest.
By analogy to our previous studies on deletion analyses in B-cellHSC7E590, HSC7E481 (PGY1, PGY3), HSC7E502, HSC7E465
(CALCR), HSC7E783 (ASNS), HSC7E911, HSC7E808, HSC7E914, chronic lymphocytic leukemia, the cut-off level was defined by the
mean / 3 standard deviations (SD) of the frequency of control cellsHSC7E737 (PLANH1), HSC7E791 (CUTL1), HSC7E329, HSC7E316,
HSC7E441, HSC7E485, HSC7E506, HSC7E572, HSC7E161 exhibiting only one fluorescence signal.24,25 The cut-off levels were
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determined for 5 representative YACs from the YAC map (range,
4.5% to 7.6%). Signal numbers were enumerated in 200 to 300
nuclei. The breakpoints of the two balanced translocations were
identified by metaphase FISH. Images were captured using a cooled
CCD camera (Xillix Technologies Corp, Richmond, British Colum-
bia, Canada).
RESULTS Fig 1. Representative partial G-banding karyotypes. (A) CML (case
no. 1) exhibiting an interstitial deletion del(7)(q11.2q22). (B) CMLG-Banding
(case no. 2) with a small interstitial deletion del(7)(q22q22). Note that
The complete karyotypes of the 21 leukemias are given bands 7q21 and 7q31 are closer to each other in the deleted than in
the normal chromosome 7 homolog. (C) MDS (case no. 3) with ain Table 2.
terminal deletion del(7)(q22). (D) MDS (case no. 6) exhibiting a recip-CML. Both CML cases were studied at diagnosis and
rocal translocation t(3;7)(p13;q22) in unstimulated bone marrow and
exhibited interstitial deletions of band 7q22 in a subclone. PHA-stimulated blood.
Case no. 1 had a proximal deletion del(7)(q11.2q22) (Fig
1A). Case no. 2 had a small deletion del(7)(q22q22) within
band 7q22 (Fig 1B).
MDS/AML. Of the 4 cases with MDS, 3 (nos. 3 through
5) had large 7q deletions; all proximal breakpoints involved
band 7q22 (Fig 1C). The remaining case (no. 6) had a bal-Table 2. Karyotypes of the 21 Myeloid Leukemias
anced translocation t(3;7)(p13;q22) that was present in un-
Tumor Karyotype
stimulated bone marrow and phytohemagglutinin (PHA)-
CML stimulated blood (Fig 1D). Of the 15 cases with de novo or
1 46,XX,t(9;22)(q34;q11)[8]/ t-AML, 14 (nos. 7 through 18, 20, and 21) had terminal or
46,XX,del(7)(q11.2q22),t(9;22)(q34;q11)[7] interstitial deletions that involved or encompassed band2 46,XY,t(9;22)(q34;q11)[7]/
7q22. The smallest deletions were identified in cases no. 1046,XX,del(7)(q22q22),t(9;22)(q34;q11)[3]
[del(7)(q22q32)] and 15 [del(7)(q22q32)], the latter withinMDS
a highly complex karyotype. One AML case (no. 17) had3 46,XY[7]/46,XY,del(7)(q22)[3]
4 46,XX[3]/46,XX,add(6)(p21),del(7)(q22q36)[7] no evaluable metaphase spreads on chromosome banding
5 46,XX,del(7)(q22)[10] analysis; in this case, the deletion was identified by in-
6* 46,XY,t(3;7)(p13;q22)[20] terphase cytogenetics with YAC clone HSC7E506.23 The
De novo AML remaining case (no. 19) had a balanced translocation
7 47,XY,del(7)(q22q36),/8[20] t(3;7)(q28;q22).
8 46,XY,del(7)(q11q36),?t(8;19)(q24;q11),del(9)(q11q22),
add(21)(p11)[5]/46,XY[15] Deletion and Translocation Mapping by FISH9 48,XY,del(3)(p21),/4,der(5)t(5;13)(q31;q12 or
14),del(7)(q22),013,/22,/mar[20] The results of the deletion/translocation mapping by FISH
10 46,XY,del(7)(q22q32)[15] are given in Fig 2. In the 19 cases of CML, MDS, and AML
11 50,XY,der(5)t(1;5)(p22;q13),del(7)(q22),/11,013, containing deletions, we identified two distinct commonly
add(16)(q2?),021,/5mar[12] deleted regions.
12 47,XY,05,del(7)(q21),/8,/r(11q?),013,add(17)(p11), CML. The commonly deleted segment in the 2 CML/mar[15]
cases extended from YAC clones HSC7E914 to HSC7E79113 45,XY,add(2)(q3?),del(3)(q21),05,del(7)(q2?1), (Fig 2). This segment was defined by case no. 2, which onder(13;21)(q10;q10),017,add(21)(p11),/r,inc[6]
banding analysis exhibited a small interstitial deletion within14 46,XX,t(2;11)(q37;q23),del(7)(q11)[21]
band 7q22 (Fig 1B). This region, which is approximately 215 45,Y,del(X)(p11),02,add(3)(q2?7),add(3)(p21),del(4)
(q21q31),05,del(7)(q22q32),add(8)(q2?4),del(9) to 3 Mb in size based on the YAC contig map, contains the
(p22),013,add(16)(p13),der(17)t(2;17)(q21;p11), genes encoding PLANH1 and CUTL1. To detect possible
/mar1,/mar2[16] submicroscopic deletions, we subsequently screened 25
16 49,XY,del(7)(q22),/8,t(8;16)(p11;p13),/13,/13[15] CML cases with normal chromosomes 7 on G-banding anal-
17† No evaluable metaphases ysis by FISH with YAC clones HSC7E737 and HSC7E791
18 46,XX,/del(1)(p22),del(7)(q11q32 or 34),013[15] from the critical region. No additional deletions of this geno-
19 46,XX[7]/46,XX,t(3;7)(q28;q22)[22]
mic region were detected in these cases.t-AML
MDS/AML. In the 17 MDS/AML cases that exhibited20 40,XY,05,06,add(7)(q?),09,add(12)(p11or13),/13,
7q22 deletions, we identified a commonly deleted segment014,015,016,016,der(?)t(?;17)(?;q21),020,022,
extending from YAC clone HSC7E329 in band 7q22 to clone/mar1,/mar2,inc[5]
21 46,XX,del(3)(q21q27),add(7)(q22),add(19)(p13)[15] HSC7E1289 in band 7q32 (Fig 2). The two different com-
monly deleted regions, which were defined by the CML* Translocation found in unstimulated bone marrow and PHA-stim-
and MDS/AML cases, are separated by a 380-kb genomiculated blood.
fragment in 7q22 recognized by YAC clone HSC7E329. The† 7q0 identified by interphase cytogenetics using clone HSC7E506
(see Fischer et al23). estimated size of the region deleted in all MDS/AML cases
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Fig 2. Mapping of deletions and translocations involving chromosome band 7q22 in 21 myeloid leukemias by FISH. del, deletion (only 1
fluorescence signal); 3, three fluorescence signals indicating the translocation breakpoint; di, disomy (2 fluorescence signals indicating retention
of both alleles); empty boxes, not done. Light grey boxes indicate the extent of the deletion. Dark grey boxes indicate the two commonly
deleted segments in CML and MDS/AML, respectively. *Clones HSC7E808 through HSC7E572 recognize a contiguous genomic fragment in
chromosome band 7q22.
is approximately 20 Mb and contains the genes encoding DISCUSSION
PRKAR2B, DRA, CAPZA2, and MET. As shown in Fig 2, Using FISH with well-mapped YAC clones, we identified
there is marked heterogeneity of the proximal deletion distinct critical genomic regions in 21 cases with various
breakpoints; within bands 7q21-q22, the breakpoints were myeloid disorders exhibiting deletions or reciprocal translo-
scattered along a large region extending from the genomic cations of chromosome band 7q22. In the 19 deletion cases,
segments recognized by clone HSC7E590 (case no. 15) to we delineated two commonly deleted segments that were
clone HSC7E316 (case no. 17). In 7 cases, the deletion defined by the CML and MDS/AML cases, respectively.
breakpoints were even proximal to band 7q21.1. In all but In the 2 cases of chronic-phase CML, we delineated a
1 case (no. 10), deletions extended distal to the genomic narrow genomic segment in band 7q22 that was deleted in
region identified by clone HSC7E1289 in band 7q32. Only both cases. This region was defined by three overlapping
the leukemic cells of case no. 10 showed two hybridization YAC clones that recognize a genomic fragment of approxi-
signals with clone HSC7E1289 and, thus, defined the distal mately 2 to 3 Mb containing the genes encoding PLANH1
border of the critical region of the MDS/AML cases. In 9 and CUTL1. The second commonly deleted region was de-
of the 17 deletion cases, we found loss of the telomeric fined by the MDS/AML cases and was localized distally to
sequences (detected by clone HSC7E526), suggesting that a the CML region. This genomic region of approximately 20
deletion of the remaining long arm of chromosome 7 had Mb encompassed the terminal part of band 7q22 and the
occurred in these cases. entire band 7q31. In contrast to the study by Kere et al,10
The breakpoint of the t(3;7)(p13;q22), which was present we did not observe a narrow breakpoint cluster region of the
in unstimulated bone marrow and PHA-stimulated blood in proximal deletion breakpoints in our MDS/AML cases. The
an MDS case (no. 6), was localized to the 400-kb genomic proximal breakpoints scattered along a large region ex-
segment recognized by YAC clone HSC7E572 (Figs 1D and tending from band 7q11 (data not shown) to band 7q22. The
3); this segment was contained in the critical region of the distal boundary of the commonly deleted segment in band
MDS/AML cases. The second translocation breakpoint, 7q32 was defined by a single case (no. 10). It is likely that
which we identified in 1 of the AML cases (no. 19) by G- both commonly deleted regions, which we identified in our
banding analysis, was localized between clones HSC7E481 study, are contained within the deleted segments that were
and HSC7E502. This genomic segment is located in band described in previous deletion mapping studies in myeloid
7q21.3 and is thus proximal to the two commonly deleted disorders.10-12 In these studies, which used RFLP and quanti-
tative Southern blot analyses, the proximal breakpoints wereregions.
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Fig 3. Identification of the
t(3;7)(p13;q22) in case no. 6 by
YAC clone HSC7E572 (Cy3). Note
the three red signals that origi-
nate from the normal chromo-
some 7 (upper left), the deriva-
tive 7 (lower left), and the
derivative 3 chromosome (upper
right). For the identification of
chromosome 3, we cohybridized
with a YAC clone (fluorescein
isothiocyanate) mapping to the
long arm of chromosome 3.
localized between the genes for EPO and PLANH1 at 7q22 analogy, the translocation breakpoint found in our MDS case
may inactivate a tumor suppressor gene, eg, by disruptionin 7 patients and between the genes for elastin and collagen
1 a 2 (COL1A2) at 7q11-q21 in another 2 patients. However, of its primary structure, in particular because it occurs in a
deletion cluster region.the distal boundaries of the deletions were less well charac-
terized. The proto-oncogene MET at band 7q31 was deleted Johnson et al13 reported on a narrow interval at band
7q22.1 in patients with MDS. The proximal breakpoint of ain all 9 cases, whereas the gene encoding the T-cell receptor
b at band 7q35 was retained in 4 of the 9 cases.11,12 constitutional inversion inv(7)(22.1q34) associated with
MDS as well as the breakpoint of a reciprocal translocationUsing FISH with a panel of mapped YAC clones from
7q, Le Beau et al9 recently delineated a 2- to 3-Mb commonly t(2;7)(p13;q22) in an unrelated patient with MDS were
found to be contained in a genomic fragment identified bydeleted genomic segment in band 7q22 in 15 patients with
myeloid or lymphoid malignancies. This segment approxi- YAC clone HSC7E783 (Table 1 and Fig 2). This finding
suggests that this genomic region contains a specific gene(s)mately corresponds to the genomic region identified by
clones HSC7E441 through HSC7E572 that is contained associated with the development of MDS. This region, which
contains the gene for the cell-cycle control enzyme ASNS,27within the critical region of the MDS/AML cases in our
study. DNA markers common to both regions include maps proximally to the translocation breakpoint in case no.
6 and to the commonly deleted segments that were identifiedD7S658, D7S796, D7S818, D7S2504, D7S2509, and
D7S2494. Interestingly, the breakpoint of the reciprocal in our study and that of Le Beau et al9 (see Fig 2). In the same
study, the breakpoints of two other balanced translocationstranslocation t(3;7)(p13;q22), which we identified in case
no. 6, not only maps to the critical segment of our MDS/ associated with MDS were localized proximally and distally
to the constitutional inversion breakpoint. In keeping withAML cases but also to the smallest overlapping deleted seg-
ment identified in the study by Le Beau et al.9 In this case these findings, we mapped the breakpoint of another bal-
anced translocation (case no. 19) between the segments iden-of MDS, the translocation was present in unstimulated bone
marrow and PHA-stimulated blood, indicating that the rear- tified by clones HSC7E481 and HSC7E502, which is proxi-
mal to the inversion breakpoint reported by Johnson et al.13rangement had occurred either in an early hematopoietic
precursor cell differentiating to the myeloid or lymphoid Taken together, the data suggest that there are multiple
genes in bands 7q21-q22 that are involved in the pathogene-lineage or in the germline and then likely predisposed the
patient to the development of MDS. This translocation sis of myeloid leukemias. Although the commonly deleted
genomic regions are still large, the identification of inversionbreakpoint may point to a novel gene of pathogenic signifi-
cance in myeloid leukemias. Translocations commonly lead and translocation breakpoints provides a first step towards
the cloning of these genes.to the activation of proto-oncogenes or to chimeric fusion
genes of oncogenic potential. However, some translocations
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